Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from younger patients with neuroblastoma.
|Neoplastic Syndrome Neuroblastoma||Genetic: gene expression analysis Genetic: protein expression analysis Other: enzyme-linked immunosorbent assay Other: immunohistochemistry staining method Other: laboratory biomarker analysis Other: medical chart review|
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Role of Stroma-Derived Soluble TßRIII in Neuroblastoma|
- Expression of TβRIII in the neuroblastic tumor and stroma of patients with advanced-stage NBL
- Correlation between TβRIII levels and TGF-β signaling correlate with NBL stage, tumor stroma content, surface TβRIII expression, and TGF-β signaling
|Study Start Date:||March 2012|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- Determine whether TβRIII expression and TGF-β signaling decrease in advanced-stage neuroblastoma (NBL) and whether these changes are confined to the Schwannian stroma.
- Determine whether sTβRIII levels and TGF-β signaling correlate with NBL stage, tumor stroma content, surface TβRIII expression, and TGF-β signaling.
OUTLINE: Archived paraffin-embedded tissue and plasma samples are analyzed for TβRIII expression, TGF-β signaling, and SMAD3 expression and phosphorylation by immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and other assays. Surface expression of TβRIII in the neuroblastic and stromal tumor components are correlated with matched circulating levels of soluble TβRIII. Results are then correlated with each patient's outcome data, including stage.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01553448
|Principal Investigator:||Gerard C. Blobe, MD, PhD||Duke University|